EAU 2023 | A randomized trial of PHOTOdynamic surgery in non–muscle-invasive bladder cancer

Rakesh Heer, PhD, FRCS(Urol), Newcastle University. Newcastle upon Tyne, London, discusses a randomized trial aimed to assess the clinical effectiveness and cost-effectiveness of photodynamic diagnosis (PDD)-guided transurethral resection of bladder tumor (TURBT) compared to standard white light (WL)-guided TURBT in patients with non-muscle-invasive bladder cancer (NMIBC) at intermediate or high risk for recurrence. A total of 538 participants were enrolled, and after a median follow-up of 44 months, the recurrence rates were similar between the PDD group and the WL group (hazard ratio 0.94, 95% CI 0.69 to 1.28, p=0.70). Three-year recurrence-free rates were 57.8% in the PDD group and 61.6% in the WL group, with no significant difference observed. Adverse events and health-related quality of life were similar between the groups. PDD-guided TURBT was also not cost-effective compared to WL-guided TURBT over a 3-year follow-up. In conclusion, PDD did not show superiority in reducing recurrence rates or cost-effectiveness when compared to WL in NMIBC patients at 3 years of follow-up. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.